TrialThe Lancet. Infectious diseases2014

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.

Iman Satti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.